Together we will lead the way to Alzheimer's first survivor.
The Judy Fund participated in a special roundtable at AAIC® featuring scientists funded by the Women's Alzheimer's Research Initiative (WARI). How inspiring and meaningful to hear directly from researchers who've been supported by your generosity to our family fund!
Dear Family and Friends,

Sixteen years ago this month, Marshall M. Gelfand established The Judy Fund in honor of our mother, Judy Gelfand, as she said goodbye to us after her long battle with Alzheimer's disease.

My father and I were determined to learn all we could about this disease and to do all that we could to end it. We have invested in research particularly in studies to determine why Alzheimer's affects more women than men.

Thanks to donors like you, The Judy Fund has raised and granted $8.4 million so far, with a goal of $10 million by 2020. With your continued support, we will reach our goal and help the Association lead the way to Alzheimer's first survivor. One of the most visible ways we see the impact of our support is at the Alzheimer's Association International Conference (AAIC).
#AAIC19 trended in Los Angeles on Twitter!
AAIC 2019 breaks records
One of the most pressing questions in Alzheimer's disease research is:  Why are two-thirds of people diagnosed with Alzheimer's women – and what are we doing to find out? This field of research is a top priority for The Judy Fund, and we are proud to lead landmark funding and support of the Alzheimer's Association's Women's Alzheimer's Research Initiative (WARI). The Judy Fund was especially honored to participate in a special roundtable discussion with a group of WARI grantees at AAIC 2019.

AAIC is the largest and most influential international meeting dedicated to advancing dementia science. Held in The Judy Fund's hometown of Los Angeles, California, AAIC2019 was perhaps the most exciting yet, with a record-setting attendance of 5,937 – 52 percent of them women! Here are a few of the incredible highlights we saw at AAIC:
  • There is new research into the differences in the progression and risk of Alzheimer's disease between women and men, including newly identified sex-specific risk genes and contrasting presentation of Alzheimer's biology in the brain. Learn more.
  • We also learned that research reported at AAIC suggests being in the paid workforce in youth and mid-life may provide women additional payout later—lower levels of cognitive decline. Learn more.
  • We received new evidence on how healthy lifestyle choices may reduce risk even in the face of other risk factors, including genetics and pollution, and provide maximum memory benefit when combined. Learn more.
  • We saw advances in emerging blood markers that may support early detection and improved diagnosis of Alzheimer's disease and other dementias and neurodegenerative diseases. Learn more.
  • We explored new clinical data from trials evaluating novel Alzheimer's treatment approaches. Learn more.
On behalf of the Gelfand family and all families affected by Alzheimer's who know that research is the key to ending this disease, thank you for your continued support of The Judy Fund.

Elizabeth Gelfand Stearns Elizabeth Gelfand Stearns
Chair, The Judy Fund
Useful Links
  The Judy Fund Website
The Judy Fund Website
Most Recent Newsletter
  The Impact of
Your Dollar

The Impact of Your Dollar
The Judy Fund Contributions to Advance Alzheimer's Research and Advocacy
The Judy Fund Contributions
Your donation will strengthen our efforts to advance Alzheimer's care, support and research. From face-to-face support to online education programs and promising global research initiatives, your gift makes a difference in the lives of all those affected by Alzheimer's and other dementias in your community and across the world. Thank you for your continued support.
Instagram Twitter Facebook

Alzheimer's Association National Office, 225 N. Michigan Ave., Fl. 17, Chicago, IL 60601
© 2019 Alzheimer's Association. All rights reserved.
800.272.3900 |® | Donate

View your email preferences or unsubscribe.